AIM: To ascertain whether resveratrol affects the expression of free fatty acids (FFA)-induced profibrogenic genes, death receptors, and/or apoptosis-related molecules in human hepatic stellate cells, using the LX-2 cell line. METHODS: Cells were cultured in the presence of FFAs (2:1 oleate : palmitate) and subsequently treated with resveratrol. Gene expression rates were determined by quantitative real-time PCR. The 50% lethal dose (LD(50)) of resveratrol in the presence of FFAs was assessed with the MTT viability test. RESULTS: Compared to vehicle controls, incubation of LX-2 cells with 0.5 mM FFAs induced profibrogenic genes (alpha-SMA x 2.9; TGF-beta1 x 1.6; TIMP-1 x 1.4), death receptors (CD95/Fas x 3.8; TNFR-1 x 1.4), and anti-apoptotic molecules (Bcl-2 x 2.3; Mcl-1 x 1.3). Subsequent addition of 15 microM resveratrol (LD(50) = 23.2 microM) significantly (P < 0.05) upregulated further these genes (alpha-SMA x 6.5; TGF-beta1 x 1.9; TIMP-1 x 2.2; CD95/Fas x 13.1, TNFR-1 x 2.1; Bcl-2 x 3.6; Mcl-1 x 1.9). Importantly, this effect was only observed in the presence of FFAs. CONCLUSION: Resveratrol amplifies the profibrogenic activation of human hepatic LX-2 stellate cells. This finding raises the possibility that in obese patients with elevated FFAs reserveratrol could provoke hepatic fibrogenesis. In-vivo studies are necessary to further validate this conclusion.
AIM: To ascertain whether resveratrol affects the expression of free fatty acids (FFA)-induced profibrogenic genes, death receptors, and/or apoptosis-related molecules in human hepatic stellate cells, using the LX-2 cell line. METHODS: Cells were cultured in the presence of FFAs (2:1 oleate : palmitate) and subsequently treated with resveratrol. Gene expression rates were determined by quantitative real-time PCR. The 50% lethal dose (LD(50)) of resveratrol in the presence of FFAs was assessed with the MTT viability test. RESULTS: Compared to vehicle controls, incubation of LX-2 cells with 0.5 mM FFAs induced profibrogenic genes (alpha-SMA x 2.9; TGF-beta1 x 1.6; TIMP-1 x 1.4), death receptors (CD95/Fas x 3.8; TNFR-1 x 1.4), and anti-apoptotic molecules (Bcl-2 x 2.3; Mcl-1 x 1.3). Subsequent addition of 15 microM resveratrol (LD(50) = 23.2 microM) significantly (P < 0.05) upregulated further these genes (alpha-SMA x 6.5; TGF-beta1 x 1.9; TIMP-1 x 2.2; CD95/Fas x 13.1, TNFR-1 x 2.1; Bcl-2 x 3.6; Mcl-1 x 1.9). Importantly, this effect was only observed in the presence of FFAs. CONCLUSION:Resveratrol amplifies the profibrogenic activation of human hepatic LX-2 stellate cells. This finding raises the possibility that in obesepatients with elevated FFAs reserveratrol could provoke hepatic fibrogenesis. In-vivo studies are necessary to further validate this conclusion.
Authors: Ariel E Feldstein; Nathan W Werneburg; Ali Canbay; Maria Eugenia Guicciardi; Steven F Bronk; Robert Rydzewski; Laurence J Burgart; Gregory J Gores Journal: Hepatology Date: 2004-07 Impact factor: 17.425
Authors: Chongwoo Yu; Young Geun Shin; Anita Chow; Yongmei Li; Jerome W Kosmeder; Yong Sup Lee; Wendy H Hirschelman; John M Pezzuto; Rajendra G Mehta; Richard B van Breemen Journal: Pharm Res Date: 2002-12 Impact factor: 4.200
Authors: Luis Bujanda; María García-Barcina; Virginia Gutiérrez-de Juan; Joseba Bidaurrazaga; Marian Fernández de Luco; Marian Gutiérrez-Stampa; Mikel Larzabal; Elisabeth Hijona; Cristina Sarasqueta; Miguel Echenique-Elizondo; Juan I Arenas Journal: BMC Gastroenterol Date: 2006-11-14 Impact factor: 3.067
Authors: Inge Mannaerts; Nathalie Eysackers; Oscar O Onyema; Katrien Van Beneden; Sergio Valente; Antonello Mai; Margarete Odenthal; Leo A van Grunsven Journal: PLoS One Date: 2013-01-31 Impact factor: 3.240